We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Best-Performing Leveraged ETF Areas of Last Week
Read MoreHide Full Article
Last week witnessed a tug-of-war between bulls and bears. While upbeat economic data points for the month of May indicated pent-up consumer demand, new U.S. cases and hospitalizations remained a cause of concerns for investors, with Texas, Arizona, Florida and Oklahoma reporting a rise in infections. Still, the government is moving ahead with reopening plans to support economic growth.
SPDR S&P 500 ETF Trust (SPY - Free Report) , SPDR Dow Jones Industrial Average ETF Trust (DIA - Free Report) and Invesco QQQ Trust (QQQ - Free Report) added about 1.9%, 1.04% and 22.4%, respectively (as of Jun 19, 2020). Against this backdrop, below we highlight a few leveraged ETF areas that shot up last week.
Pharma & Biotech
The global pharma and biotech companies are busy formulating treatments and vaccines for the virus, making the sector most lucrative. The U.S. government is assisting efforts from companies including Moderna (MRNA) and Johnson & Johnson (JNJ), as well as London-based AstraZeneca Plc (AZN) and France’s Sanofi (SNY).
Talks are rife that the White House and FDA will okay approval of one or two COVID-19 vaccines to help bolster Donald Trump’s chances before the U.S. presidential election in November, while scientists expect it around early 2021.
Promising vaccine data boosted Chinese pharma stocks last week. Wall Street analysts expect more companies entering the clinical trial phase I in the coming weeks. Overall, ProShares Ultra Nasdaq Biotechnology (BIB - Free Report) (up 15.3%) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL - Free Report) (up 14.9%) and Direxion Daily Healthcare Bull 3X Shares (CURE - Free Report) gained materially last week.
Internet
Internet stocks have all the more reason to surge now as these have less to do with human contact. The coronavirus scare favored the online retailing industry as lockdowns and quarantines boosted demand for online shopping and other kinds of Internet activities.
No wonder,Direxion Daily CSI China Internet Bull 2X Shares (CWEB - Free Report) (up 17.62%), Direxion Daily Dow Jones Internet Bull 3X SharesWEBL (up 13.4%) and MicroSectors FANG+ Index 3X Leveraged ETN (FNGU - Free Report) (up 11.4%) were the winners past week.
Nasdaq
Tech-heavy Nasdaq remained strong on fears of a second wave of coronavirus that charged up stay-at-home tech stocks. Moreover, big tech companies are now eyeing the virus-testing & tracing business (read: Big Techs Making the Most of Medical Emergency: ETFs to Win).
Verily Life Sciences, a sister company of Google, is now launching a health screening and analytics service for businesses trying to safely reopen during the pandemic. Microsoft (MSFT - Free Report) recently stated that it has expanded its network and data center capacity to meet growing demand for cloud services amid the ongoing coronavirus pandemic.
ProShares UltraPro QQQ (TQQQ - Free Report) (up 10.75%), Direxion Daily Technology Bull 3X Shares (TECL - Free Report) (up 8.95%) and MicroSectors FANG+ Index 2X Leveraged ETN (FNGO - Free Report) (up 7.8%) gained the maximum in this segment.
Consumer Staples
The sector has been a winner during the coronavirus outbreak. With a second wave showing signs of hitting some U.S. states massively, risk-off trade sentiments started prevailing in Wall Street. Naturally, the safe and non-cyclical sector consumer staples surged last week. Direxion Daily Consumer Staples Bull 3X Shares ETFNEED added 8.5% last week.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
4 Best-Performing Leveraged ETF Areas of Last Week
Last week witnessed a tug-of-war between bulls and bears. While upbeat economic data points for the month of May indicated pent-up consumer demand, new U.S. cases and hospitalizations remained a cause of concerns for investors, with Texas, Arizona, Florida and Oklahoma reporting a rise in infections. Still, the government is moving ahead with reopening plans to support economic growth.
SPDR S&P 500 ETF Trust (SPY - Free Report) , SPDR Dow Jones Industrial Average ETF Trust (DIA - Free Report) and Invesco QQQ Trust (QQQ - Free Report) added about 1.9%, 1.04% and 22.4%, respectively (as of Jun 19, 2020). Against this backdrop, below we highlight a few leveraged ETF areas that shot up last week.
Pharma & Biotech
The global pharma and biotech companies are busy formulating treatments and vaccines for the virus, making the sector most lucrative. The U.S. government is assisting efforts from companies including Moderna (MRNA) and Johnson & Johnson (JNJ), as well as London-based AstraZeneca Plc (AZN) and France’s Sanofi (SNY).
Talks are rife that the White House and FDA will okay approval of one or two COVID-19 vaccines to help bolster Donald Trump’s chances before the U.S. presidential election in November, while scientists expect it around early 2021.
Promising vaccine data boosted Chinese pharma stocks last week. Wall Street analysts expect more companies entering the clinical trial phase I in the coming weeks. Overall, ProShares Ultra Nasdaq Biotechnology (BIB - Free Report) (up 15.3%) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL - Free Report) (up 14.9%) and Direxion Daily Healthcare Bull 3X Shares (CURE - Free Report) gained materially last week.
Internet
Internet stocks have all the more reason to surge now as these have less to do with human contact. The coronavirus scare favored the online retailing industry as lockdowns and quarantines boosted demand for online shopping and other kinds of Internet activities.
No wonder,Direxion Daily CSI China Internet Bull 2X Shares (CWEB - Free Report) (up 17.62%), Direxion Daily Dow Jones Internet Bull 3X Shares WEBL (up 13.4%) and MicroSectors FANG+ Index 3X Leveraged ETN (FNGU - Free Report) (up 11.4%) were the winners past week.
Nasdaq
Tech-heavy Nasdaq remained strong on fears of a second wave of coronavirus that charged up stay-at-home tech stocks. Moreover, big tech companies are now eyeing the virus-testing & tracing business (read: Big Techs Making the Most of Medical Emergency: ETFs to Win).
Verily Life Sciences, a sister company of Google, is now launching a health screening and analytics service for businesses trying to safely reopen during the pandemic. Microsoft (MSFT - Free Report) recently stated that it has expanded its network and data center capacity to meet growing demand for cloud services amid the ongoing coronavirus pandemic.
ProShares UltraPro QQQ (TQQQ - Free Report) (up 10.75%), Direxion Daily Technology Bull 3X Shares (TECL - Free Report) (up 8.95%) and MicroSectors FANG+ Index 2X Leveraged ETN (FNGO - Free Report) (up 7.8%) gained the maximum in this segment.
Consumer Staples
The sector has been a winner during the coronavirus outbreak. With a second wave showing signs of hitting some U.S. states massively, risk-off trade sentiments started prevailing in Wall Street. Naturally, the safe and non-cyclical sector consumer staples surged last week. Direxion Daily Consumer Staples Bull 3X Shares ETF NEED added 8.5% last week.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>